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ABSTRACT: The impact of covalent binding on PROTAC-mediated degradation of BTK was investigated through the preparation 
of both covalent binding and reversible binding PROTACs derived from the covalent BTK inhibitor ibrutinib. It was determined that 
a covalent binding PROTAC inhibited BTK degradation despite evidence of target engagement, while BTK degradation was observed 
with a reversible binding PROTAC. These observations were consistently found when PROTACs were employed that were able to 
recruit either IAP or cereblon E3 ligases. Proteomics analysis determined that use of a covalently bound PROTAC did not result in 
the degradation of covalently bound targets, whilst degradation was observed for some reversibly bound targets. This observation 
highlights the importance of catalysis on successful PROTAC-mediated degradation, and highlights a potential caveat for the use of 
covalent target binders in PROTAC design.
Protein degrading bifunctional molecules are emerging as a novel drug discovery strategy with the potential to offer pharma-
cologic control of biology that is not currently achievable with existing small molecule medicines.1-3 Mechanistic hallmarks of 
proteolysis-targeting chimeras (PROTACs) include high cellular degradation potency (DC50, the concentration at which 50% 
of substrate is degraded) high target selectivity, and extended pharmacodynamic duration of action that is dependent upon both 
drug pharmacokinetics and target protein resynthesis rate.4, 5 The targeted protein degradation paradigm is driven by the ability 
of PROTACs to catalytically promote the degradation of a desired protein in an event-driven process. This contrasts with 
occupancy-driven pharmacology that is characteristic of traditional small molecule inhibitors.3  
The catalytic mechanism of PROTAC-mediated protein degradation (Figure 1, blue arrows) has been speculated as being 
fundamental to the high degradation efficiency observed in both in vitro and in vivo models.1 This catalytic paradigm creates 
opportunities to deliver novel medicines with very low doses.3 However, in principle it may also be possible for a covalent 
binding PROTAC to act as a stoichiometric degrader, resulting in degradation of one protein molecule per PROTAC molecule 
(Figure 1, green arrows). To explore this hypothesis, the effect of covalent binding on PROTAC-mediated degradation of 
Bruton’s tyrosine kinase (BTK) was tested. BTK was chosen as an exemplar protein target, as it has previously been shown to 
be degradable via the PROTAC approach.6, 7, 8-10 It was envisioned that comparison of structurally similar covalent and non-
covalent PROTACs that bind to BTK would elucidate whether the catalytic element of the PROTAC mechanism is important 
for the efficient degradation of this target. This is important because if stoichiometric PROTACs can be designed for less-
tractable targets through the use of covalent target binders to enhance target binding affinity, then this would represent a novel 
approach for tackling the “undruggable” proteome.11, 12 
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Figure 1. Proposed PROTAC mechanism for catalytic reversible PROTACs (blue) and non-catalytic covalent PROTACs 
(green). 
Covalent-binding PROTACs have previously been shown to be functional target degraders. For example, HaloPROTACs 
containing a chloroalkane designed to covalently bind to a HaloTag target protein fusion have been used to investigate target 
degradability.13 This method has been shown to induce degradation of specific fusion proteins by recruitment of the E3 ligases 
VHL13 and IAP.14 Additionally, ERK1/2 was degraded employing a covalent-binding moiety as the targeting element, although 
covalent binding to ERK1/2 was not confirmed.15 Although illustrative, these reports do not employ a reversibly binding con-
trol compound, therefore the impact of covalent vs. reversible target binding on target degradation cannot be fully character-
ised.  
The current study employs covalent BTK binding moieties chosen such that the covalent-binding element can be removed by 
formal reduction while still maintaining potent reversible BTK binding and inhibition.16 This design element allows for a valid 
comparison of reversible and covalent PROTACs for this target.10, 17 The covalent BTK inhibitor ibrutinib 1a and reversibly 
binding analogue 1b16 were selected for elaboration into PROTACs 2 and 3, respectively employing a moiety that binds and 
recruits E3 ligases from the inhibitor of apoptosis proteins (IAP) family.18 The acrylamide moiety of ibrutinib 1a was selected 
as a viable linkage point to the E3 ligase binder due to its solvent exposure in the co-crystal structure of BTK and ibrutinib 
1a,19 and its use in fluorescent ligands or bioorthogonal probes which maintain BTK binding activity.16, 18, 20 This resulted in 
ibrutinib-based PROTAC 2 and the corresponding reduced acrylamide analogue 3 as a reversible PROTAC control (Figure 
2). PROTACs 2 and 3 were both observed to have biochemical inhibitory activity against BTK (Supplementary Figure 1). 
PROTAC 2 was found to covalently modify recombinant BTK in vitro, as evidenced by intact protein MS, whilst the saturated 
acrylamide analog 3 was not observed to covalently modify BTK, as expected (Supplementary Figure 2).  
 
 
Figure 2: Ibrutinib 1a, reversible BTK inhibitor 1b, covalent BTK binding PROTAC 2, and reversible BTK binding PROTAC 3.  
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Both the covalently binding PROTAC 2 and the reversible PROTAC 3 were examined for their ability to cause BTK degrada-
tion. THP-1 cells were selected as IAP-mediated degradation of BTK had previously been observed in this cell line.21 No BTK 
degradation was observed upon treatment of THP-1 cells with the covalent PROTAC 2 at increasing concentrations from 1 nM 
up to 10 M for 16 h. (Figure 3a). In contrast, THP-1 cell treatment with the reversible PROTAC 3 caused concentration 
dependent reduction in BTK levels with an approximate DC50 of 200 nM (Figure 3b). Ibrutinib itself (compound 1a) was not 
found to induce BTK degradation (Supplementary Figure 4). BTK degradation caused by reversible PROTAC 3 was found 
to be time dependent in a time course experiment, whilst extended treatment with covalent PROTAC 2 did not result in a 
significant change to BTK protein levels (Supplementary Figure 5).  
(a)  
(b)  
Figure 3: (a) Representative immunoblot of BTK following 16 h incubation with covalent PROTAC 2 at increasing concen-
trations (b) Representative immunoblot of BTK following 16 h incubation with reversible PROTAC 3 at increasing concentra-
tions. Experiments were conducted in THP-1 cells with β-tubulin as a loading control (n = 3, see Supplementary Figure 3). 
By appropriate selection of cell line, cellular target engagement can be assessed for both the target protein and the E3 ligase 
for PROTAC compounds 2 and 3. Kinase domain occupancy of BTK has been shown to correlate with inhibition of BTK 
autophosphorylation at Y223 following BCR pathway stimulation.18 Similarly, engagement of the recruited E3 ligase IAP can 
be assessed, since inhibition of cIAP1 causes its auto-ubiquitination and degradation.22 THP-1 cells are not sensitive to BCR 
pathway stimulation, therefore this assessment was conducted in Ramos cells.23 Following stimulation of the BCR pathway 
with -IgM in Ramos cells and treatment with covalent PROTAC 2, concentration dependent reduction of both pBTK Y223 
and cIAP1 were observed suggesting engagement of both target protein and E3 ligase at concentrations above 30 nM, however 
no degradation of BTK was observed (Figure 4). Above concentrations of 300 nM, almost complete inhibition of pBTK Y223 
was observed, suggesting full occupancy of the kinase domain. At this concentration, it would be expected that BTK degrada-
tion would occur in a stoichiometric manner, however there was no observed change to total BTK protein levels, suggesting 
the lack of BTK degradation is not due to the lack of PROTAC catalysis. For the reversible PROTAC 3, cIAP1 levels were 
also reduced at concentrations greater than 30 nM, suggesting effective IAP target engagement and similar cellular penetration 
as the covalent binding PROTAC 2. However, BTK autophosphorylation was reduced only at 300 nM suggesting weaker 
kinase binding as compared to 2, as expected upon reduction of the acrylamide covalent binding moiety. Despite evidence of 
reduced BTK target binding, significant BTK degradation was observed upon treatment with the reversible PROTAC 3 at 
concentrations greater than 300 nM. Ibrutinib 1a was again found to have no effect on total protein levels in Ramos cells 
(Supplementary Figure 4). The effect of covalent binding on induced BTK degradation was consistent across tested hetero-
bivalent BTK-IAP PROTACs, and was not found to be linker length dependent (Supplementary Figure 7). Degradation of 
BTK was confirmed to be a result of IAP ligase family recruitment, since diastereomers of PROTACs 2 and 3 employing the 
inactive enantiomer of the parent IAP inhibitor did not degrade BTK at all concentrations tested (Supplementary Figure 8).  
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Figure 4: Representative immunoblots of BTK, pBTK Y223, cIAP1 following 16 h incubation in Ramos cells with PROTACs 
2 or 3 following BCR pathway stimulation with α-IgM. Experiments were conducted in Ramos cells with β-tubulin as a loading 
control (n = 3, see Supplementary Figure 6). 
To assess if the inability of covalent binding PROTAC 2 to degrade BTK was restricted to recruitment of IAP E3 ligases, 
ibrutinib-based PROTACs incorporating a cereblon binding motif were also prepared (Figure 5A). Multiplexed protein dy-
namics profiling experiments were carried out in Ramos cells with 24 h incubation of covalent and reversible cereblon-based 
PROTACs 4 and 5, respectively.24 This approach allows determination of differential effects of compound treatment on the 
proteome both on mature protein levels, and on de novo nascent protein synthesis. This allows detection of targets that are 
specifically degraded by a functional PROTAC, as these targets would show a reduction in the abundance of both mature and 
nascent protein levels, whereas downstream transcriptional or translational regulation will be detected by a reduction only in 
nascent protein levels. Neither ibrutinib 1a nor the reversible BTK inhibitor 1b showed any effect on either mature or nascent 
protein levels at 1 µM (Figure 5B and Supplementary Figure 9). Covalent PROTAC 4 showed no effect on BTK levels, but 
induced the degradation of CSK and LYN at 10 µM (concentration response presented in Supplementary Figure 9). Both 
CSK and LYN are SRC kinases reversibly bound by ibrutinib 1a; both CSK and LYN lack the conserved cysteine present in 
the BTK kinase domain, suggesting that covalent PROTAC 4 can successfully degrade targets to which it binds with sufficient 
affinity in a non-covalent manner, though with some selectivity given the promiscuous nature of the warhead, demonstrated 
previously in our laboratories.16 The reversible PROTAC 5 was observed to cause the degradation of BTK, as well as to induce 
the degradation of CSK, LYN and LAT2 at 10 µM (concentration response presented in Supplementary Figure 9). Addition-
ally, downregulation of CD19 and INPP5D (SHIP1) expression was observed in the nascent protein pool, but not in the mature 
pool of proteins. Both LAT2 and CD19 have been reported as being directly involved in BCR signaling, and their translational 
regulation could plausibly be influenced by the degradation of BTK by PROTAC 5.25-27 Additionally, SHIP1 has been reported 
to play a role in phosphoinositol signaling upstream of BTK, and the translational regulation of SHIP1 may be influenced by 
the degradation of BTK by PROTAC 5.28 Alternatively, the role of LYN in SHIP1 tyrosine phosphorylation and activation 
could result in the translational downregulation of SHIP1. The protein degradation profile induced by both PROTAC 4 and 5 
is concentration dependent, as reflected in BTK, CSK and LYN levels (Figure 5C; concentration response presented in Sup-
plementary Figure 9), and demonstrates that the effect of covalency on degradation was reproducible between both IAPs and 
cereblon E3 ligases. 
 
A) 
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Figure 5: A) Cereblon PROTACs targeting BTK (PROTACs 4 and 5). B) Multiplexed proteome dynamics profiling of Ramos 
cells upon PROTAC treatment. Ramos cells were incubated with either ibrutinib 1a (1 µM), covalent PROTAC 4 (10 µM) or 
reversible PROTAC 5 (10 µM) for 24 h. Discrimination of mature and nascent proteins was enabled by a pulse SILAC ap-
proach. The graphs show fold change values (log2 scale) of abundance compared to the vehicle control of replicate 2 over 
replicate 1 for each condition. Effects on mature proteins and nascent proteins are shown in the upper panels framed in orange 
and in the lower panels framed in blue, respectively. Proteins significantly regulated in at least one condition (fold change ≥ 
33 % and p value ≤ 0.05) are marked in red. C) Multiplexed proteome dynamics profiling of Ramos cells upon compound 
treatment, showing fold change values (log2 scale) for representative replicate 2 for BTK, CSK and LYN. Cellular treatment 
with ibrutinib 1a or the reversible ibrutinib analogue 1b (1 µM), compound 4 (0.1, 1 and 10 µM), and compound 5 (0.1, 1 and 
10 µM).  
The lack of PROTAC-mediated degradation of BTK observed with ibrutinib-derived covalent binding PROTACs 2 and 4 
highlights a potential caveat for covalent-based approaches for the induction of targeted protein degradation, as our experiments 
show that irreversible target binding blocks IAP or cereblon-mediated degradation of this target. Potential explanations for this 
unusual effect may be that the covalently bound ligand blocks ubiquitin transfer onto a surface lysine required for degradation, 
or the covalent protein modification blocks the presentation of the intrinsically disordered region required for recognition by 
the proteasome.29 In contrast, PROTACs that reversibly bind to BTK can induce the degradation of BTK, but may not induce 
the degradation of other kinases bound by the molecule, as suggested by the results observed with PROTAC 5, and separately 
by Crews and Gray.6, 7 This work suggests that despite literature evidence indicating that PROTAC molecules can successfully 
induce the degradation of covalently bound protein targets,13, 14 different factors likely play a significant role in the degradation 
of covalently bound PROTAC targets as compared to reversibly bound PROTAC targets. 
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